To investigate the incidence of ovarian metastasis in endometrial carcinoma (EC) and analyze its risk factors and provide a theoretical basis for whether retention of the ovary in patients with EC.
A systematic search using synonyms of ‘ovarian cancer’ and ‘metastasis' was conducted in PubMed, Cochrane database, Embase, Google Scholar, and WOS database. Meta-analysis was performed on 7 included studies, comprising 4281 clinical-stage I-IV EC patients. Studies were assessed using the Newcastle–Ottawa Scale (NOS) criteria. Odds risks (OR) and 95% confidence intervals (CI) were calculated using an inverse variance weighted random-effects model.
The ovarian metastasis risk of EC was significantly higher for patients with myometrial invasion >1/2 (OR = 18.19, 95% CI 5.34 to 61.96 compared to myometrial invasion ≤1/2), any pelvic lymph node invasion (PLNI) (OR = 5.41, 95% CI 2.60–10.97 compared to without PLNI), G3 pathological grade (OR = 2.66, 95%CI 1.35–5.24 compared to G1-G2), non-endometrioid pathological type (OR = 6.46, 95% CI 3.25 to 12.83 compared to endometrioid), lymphatic vascular space invasion (LVSI) (OR = 6.46, 95% CI 3.25 to 12.83 compare to without LVSI), age >45 (OR = 2.01, 95% CI 0.29 to 14.11 compared to age ≤45), and cervical invasion (OR = 4.12, 95% CI 1.87 to 9.08 compared to without cervical invasion).
About 4.95% of EC patients develop ovarian metastasis. Age >45, myometrial invasion >1/2, cervical invasion, PLNI, pathological type, G3 pathological grade, and LVSI were the high-risk factors for ovarian metastasis of EC. Ovarian preservation should be carefully selected for patients with EC, and preoperative and intraoperative evaluations should be entirely performed.
Abbreviations:EC (endometrial carcinoma), MI (myometrial invasion), PLNI (pelvic lymph node invasion), LVSI (lymphatic vascular space invasion), OR (Odds risks), 95% CI (95% confidence intervals)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA: Cancer J Clinicians. 2021; 71: 209-249
- Cancer statistics, 2021.CA: Cancer J Clinicians. 2021; 71: 7-33
- International patterns and trends in endometrial cancer incidence, 1978-2013.J Natl Cancer Inst. 2018; 110: 354-361
- Annual report to the nation on the status of cancer, 1975-2014, featuring survival.J Natl Cancer Inst. 2017; : 109
- Annual report to the nation on the status of cancer, part I: national cancer statistics.Cancer. 2018; 124: 2785-2800
- Springer, New York1987: 742-768 Metastatic tumors of the ovary.
- A preoperative prediction model for predicting coexisting adnexa malignancy of patients with G1/G2 endometrioid endometrial cancer.Gynecol Oncol. 2020; 159: 402-408
- European society of gynecological oncology task force for fertility preservation: clinical recommendations for fertility-sparing management in young endometrial cancer patients.Int J Gynecol Cancer. 2015; 25: 1258-1265
- Ovarian metastasis in endometrial carcinoma.Gynecol Oncol. 1998; 70: 183-187
- Retrospective analysis on coexisting ovarian cancer in 976 patients with clinical stage I endometrial carcinoma.J Obstet Gynaecol Res. 2011; 37: 352-358
- Ovarian metastasis in endometriod type endometrial cancer.Int J Fertil Steril. 2011; 5: 148-151
- Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.Gynecol Oncol. 2012; 125: 477-482
- Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature.Gynecol Oncol. 2012; 125: 263-270
- Lives in the balance: women with cancer and the right to fertility care.J Clin Oncol. 2013; 31: 668-669
- Prophylactic oophorectomy in premenopausal women and long-term health.Menopause Int. 2008; 14: 111-116
- Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study.Gynecol Oncol. 2010; 118: 283-288
- The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses.Ottawa Hospital Research Institute, 2011
- Ovarian metastasis in patients with endometrial cancer: risk factors and impact on survival.J Cancer Res Clin Oncol. 2018; 144: 1103-1107
- Risk factors for ovarian involvement in young and premenopausal endometrioid endometrial cancer patients.Eur J Obstetrics, Gynecol Reprod Biol. 2018; 222: 151-154
- Ovarian preservation in young women with endometrial cancer of endometrioid histology.Acta Obstetricia Gynecol Scand. 2015; 94: 430-434
- Feasibility of ovarian preservation in patients with early stage endometrial carcinoma.Gynecol Oncol. 2007; 104: 52-57
- Synchronous primary cancers of the endometrium and ovary in young women: a Korean Gynecologic Oncology Group Study.Gynecol Oncol. 2013; 131: 624-628
- Coexisting ovarian malignancy in patients with clinical stage I endometrial carcinoma.Archiv Gynecol Obstetrics. 2012; 286: 1241-1245
- Preoperative predictive factor analysis of ovarian malignant involvement in premenopausal patients with clinical stage I endometrioid endometrial carcinoma.Sci Rep. 2021; 11: 1219
- Coexisting ovarian malignancy in young women with endometrial cancer.Obstetrics Gynecol. 2005; 106: 693-699
- Risk factors for pelvic lymph node metastasis in endometrial cancer.Arch Gynecol Obstetrics. 2019; 300: 1007-1013
- Lymph node metastasis in patients with endometrioid endometrial cancer: overtreatment is the main issue.Int J Gynecol Cancer. 2017; 27: 748-753
- The effect of myometrial invasion on prognostic factors and survival analysis in endometrial carcinoma.Afr Health Sci. 2019; 19: 3235-3241
- Cervical invasion, lymphovascular space invasion, and ovarian metastasis as predictors of lymph node metastasis and poor outcome on stages I to III endometrial cancers: a single-center retrospective study.World J Surg Oncol. 2019; 17https://doi.org/10.1186/s12957-019-1733-2
- Comparison and analysis of the clinicopathological features of SCEO and ECOM.J Ovarian Res. 2019; 12: 10
- High-grade Endometrioid Carcinoma of the Ovary: A Clinicopathologic Study of 30 Cases.Am J Surg Pathol. 2018; 42: 534-544
- Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.Gynecol Oncol. 2019; 155: 39-50
- Pathologic Staging of Endometrial Carcinomas: Selected Areas of Difficulty.Adv Anat Pathol. 2018; 25: 71-84
- The significance of adnexal involvement in endometrial carcinoma.Gynecol Oncol. 1999; 74: 74-79
- Positive peritoneal cytology is highly predictive of prognosis and relapse patterns in stage III (FIGO 2009) endometrial cancer.Gynecol Oncol. 2013; 130: 49-53
Published online: November 12, 2021
Accepted: November 8, 2021
Received in revised form: October 16, 2021
Received: September 1, 2021
© 2021 Elsevier B.V. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Corrigendum to “Ovarian metastasis risk factors in endometrial carcinoma: A systematic review and meta-analysis” [Eur J Obstet Gynecol Reprod Biol 267 (2021) 245–255]European Journal of Obstetrics and Gynecology and Reproductive BiologyVol. 269